STOCK TITAN

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

LAVA Therapeutics, a clinical-stage immuno-oncology company, will participate in the Jefferies Global Healthcare Conference. Stephen Hurly, President and CEO, will represent the company in a fireside chat on June 5, 2024, at 8:00 a.m. ET. The discussion will be available via webcast on the company's investor relations website. The webcast replay will be archived for 90 days following the event. LAVA focuses on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers.

Positive
  • LAVA Therapeutics' participation in a major healthcare conference highlights its industry presence and can attract investor interest.
  • The webcast offers transparency and accessibility to potential investors who can review the company's presentation for 90 days.
  • The proprietary Gammabody® platform emphasizes innovation in immuno-oncology, which could drive future growth.
Negative
  • The announcement lacks specific financial or clinical trial updates, which might be deemed as a non-substantive event by investors.
  • Participation in conferences, without concrete data or results, might not significantly impact stock performance.

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference.

Presentation Details
Format: Fireside Chat
Date: Wednesday, June 5, 2024
Time: 8:00 a.m. ET

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events. The replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.

A Phase 1/2a dose escalation trial (NCT05369000) to evaluate the lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States in a trial evaluating monotherapy and with interleukin-2 (IL-2). The Company is also expanding the Phase 1/2a study to include a combination arm with KEYTRUDA®(pembrolizumab), through a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. The Company licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for clinical development and commercialization. The pipeline also includes several pre-clinical programs. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedInX, and YouTube.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA

Gammabody® is a registered trademark of LAVA Therapeutics N.V.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

LifeSci Advisors (IR/Media)
Joyce Allaire
Jallaire@lifesciadvisors.com 


FAQ

What event is LAVA Therapeutics participating in?

LAVA Therapeutics is participating in the Jefferies Global Healthcare Conference.

When will LAVA Therapeutics present at the Jefferies Global Healthcare Conference?

LAVA Therapeutics will present on June 5, 2024, at 8:00 a.m. ET.

Who will represent LAVA Therapeutics at the Jefferies Global Healthcare Conference?

Stephen Hurly, President and CEO of LAVA Therapeutics, will represent the company.

How can I access the webcast of LAVA Therapeutics’ fireside chat?

The webcast can be accessed under the 'Events' tab on the investor relations section of the LAVA Therapeutics website.

How long will the webcast replay of the LAVA Therapeutics presentation be available?

The webcast replay will be archived for 90 days following the presentation date.

LAVA Therapeutics N.V. Ordinary Shares

NASDAQ:LVTX

LVTX Rankings

LVTX Latest News

LVTX Stock Data

48.12M
26.29M
28.72%
32.62%
0.01%
Biotechnology
Healthcare
Link
United States of America
Utrecht